CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharma Holdings, Inc. Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.) incorporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China) None Securities registered under Section 12(b) of the] [Anhui Fuyang Xinte Pharmaceutical Company , S ales Contract Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Tiopronin kg 1200.00 1000 1200000 Hepatocyte growth—promoting factor kg 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only 5,121,000.00] [Raw Material Purchase / Sales Contract Date signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Parties agree to the term and condition stated as following, 1 Name, specification, quantity and total amount of product Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid ml 2.00 873,950 1,747,900.00 FDHB mg 400.00 7,300] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity ,Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of Shipment Buflomedil] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity, Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer EX-31.2 7 cph10kex312123109.htm] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer EX-32.1 8 cph10kex321123109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer EX-32.2 9 cph10kex322123109.htm]

By | 2016-03-03T20:51:20+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: Form 10-K (Mark one) x For the fiscal

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharma Holdings, Inc. Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.) incorporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China) None Securities registered under Section 12(b) of the] [Anhui Fuyang Xinte Pharmaceutical Company , S ales Contract Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Tiopronin kg 1200.00 1000 1200000 Hepatocyte growth—promoting factor kg 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only 5,121,000.00] [Raw Material Purchase / Sales Contract Date signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Parties agree to the term and condition stated as following, 1 Name, specification, quantity and total amount of product Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid ml 2.00 873,950 1,747,900.00 FDHB mg 400.00 7,300] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity ,Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of Shipment Buflomedil] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity, Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer EX-31.2 7 cph10kex312123109.htm] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer EX-32.1 8 cph10kex321123109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer EX-32.2 9 cph10kex322123109.htm]

By | 2016-03-03T20:52:21+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharmas, Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.)orporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China)] [Anhui Fuyang Xinte Pharmaceuticalmpany , Sesntract Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Tiopronin 1200.00 1000 1200000 Hepatocyte growthpromoting factor 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only] [Raw Material Purchase /lesntractte signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Partiesree to the term andndition stated following, 1 Name,ecification, quantity and total amount of product Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity ,Specifications Unit Quantity] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity,ecifications] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2)Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer cph10kex312123109.htm 7 EX-31.2] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer cph10kex321123109.htm 8 EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer cph10kex322123109.htm 9 EX-32.2]

By | 2016-02-07T23:43:37+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: Form 10-K (Mark one) x For the fiscal

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharmas, Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.)orporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China)] [Anhui Fuyang Xinte Pharmaceuticalmpany , Sesntract Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Tiopronin 1200.00 1000 1200000 Hepatocyte growthpromoting factor 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only] [Raw Material Purchase /lesntractte signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Partiesree to the term andndition stated following, 1 Name,ecification, quantity and total amount of product Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity ,Specifications Unit Quantity] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity,ecifications] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2)Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer cph10kex312123109.htm 7 EX-31.2] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer cph10kex321123109.htm 8 EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer cph10kex322123109.htm 9 EX-32.2]

By | 2016-02-07T23:44:27+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] EFFECT: (Original Filing)

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]

By | 2016-03-03T20:54:53+00:00 February 24th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] EFFECT: .FormData {color: blue; background-color: white; font-size: small; font-family:

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]

By | 2016-03-03T20:56:56+00:00 February 24th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] EFFECT: (Original Filing)

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica,ns-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica,ns-serif} .FormTitle {font-size: medium; font-family: arial, helvetica,ns-serif; font-weight: bold} .FormName {font-size: large; font-family: arial,]

By | 2016-02-07T23:45:04+00:00 February 24th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] EFFECT: .FormData {color: blue; background-color: white; font-size: small; font-family:

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica,ns-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica,ns-serif} .FormTitle {font-size: medium; font-family: arial, helvetica,ns-serif; font-weight: bold} .FormName {font-size: large; font-family: arial,]

By | 2016-02-07T23:45:56+00:00 February 24th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G/A: (Original Filing)

[CUSIP No. 16941T104 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OFOVE PERSONS (ENTITIES ONLY) Peter Siris 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A (SEE INSTRUCTIONS) (a)[_] (b)[X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH]

By | 2016-02-07T23:46:54+00:00 February 16th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar